PT-141 (Bremelanotide): The Complete 2026 Guide to Dosing, Benefits & Sexual Health

PT-141 — sold under the brand name Vyleesi — is the first FDA-approved drug that works inside the brain to enhance sexual desire. Unlike Viagra, Cialis, or testosterone, it doesn't touch blood vessels or hormones. Instead, it activates melanocortin receptors in the hypothalamus and limbic system, triggering a cascade that increases dopamine signaling in the brain's desire circuitry. For women with hypoactive sexual desire disorder (HSDD), it's a prescription option. For men, it's increasingly used off-label — and the science behind it is compelling.

This guide covers everything: how PT-141 works, what the clinical trials showed, dosing protocols for men and women, side effects, interactions with ED medications, and how it's accessed through compounding pharmacies.

What Is PT-141 (Bremelanotide)?

Bremelanotide is a synthetic heptapeptide — a chain of seven amino acids — derived from Melanotan II (MT-II). It was originally developed as a sunless tanning agent, but researchers noticed a striking side effect in early trials: both men and women reported spontaneous sexual arousal. That finding redirected the compound's development entirely.

PT-141 is a cyclic peptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Its cyclic structure makes it more metabolically stable than linear peptides, with a half-life of approximately 2.7 hours and a duration of action lasting 4–6 hours.

In 2019, the FDA approved bremelanotide (Vyleesi) for generalized, acquired hypoactive sexual desire disorder in premenopausal women — making it one of only two FDA-approved drugs for female sexual dysfunction, alongside flibanserin (Addyi).

Mechanism of Action: How PT-141 Works in the Brain

PT-141 is a non-selective agonist at melanocortin receptors MC1R through MC5R — with particular affinity for MC3R and MC4R. The MC4 receptor is the key target for its sexual effects.

MC4R is densely expressed in the hypothalamus, specifically in the medial preoptic area (MPOA) and paraventricular nucleus (PVN) — regions heavily involved in the regulation of sexual motivation. When bremelanotide binds MC4R, it triggers downstream signaling that:

• Increases dopamine release in the MPOA and nucleus accumbens (the brain's reward center)
• Modulates oxytocin release from the PVN
• Sends descending neural signals through the spinal cord to the pelvic organs, increasing parasympathetic tone

In men, this translates to penile erection — achieved without nitric oxide or cGMP pathways. That distinction is critical: PT-141 can produce erections even when PDE5 inhibitors like sildenafil fail, because it bypasses the vascular mechanism entirely and works upstream at the level of neural desire.

In women, the same pathway increases genital blood flow, lubrication, and — most importantly — subjective sexual desire. This is the therapeutic target for HSDD: not the mechanics of arousal, but the felt sense of wanting sex in the first place.

Clinical Evidence

RECONNECT Trials (Women with HSDD)

The FDA approval was based on two Phase 3 randomized controlled trials collectively called RECONNECT. Across both studies, bremelanotide 1.75 mg produced statistically significant improvements in:

• Desire domain score (Female Sexual Function Index): +0.5 vs. placebo
• Distress score (Female Sexual Distress Scale-Desire): −0.3 vs. placebo

These effect sizes appear modest in absolute terms but were clinically meaningful for a substantial proportion of participants. A 52-week open-label extension study confirmed the durability of effect and the safety profile over long-term use, with no evidence of tolerance development.

Men and Erectile Dysfunction

Several Phase 2 trials examined bremelanotide in men with psychogenic and organic ED. A landmark study by Diamond et al. (2004) showed that intranasal bremelanotide (then called PT-141) produced dose-dependent erections in men with moderate ED, with 60% of subjects achieving erections sufficient for sexual activity at the 10 mg intranasal dose.

A subsequent study examined the combination of bremelanotide and sildenafil in men who were inadequate responders to sildenafil alone. The combination produced "a clinically significant enhanced erectile response" beyond what sildenafil alone achieved — suggesting a synergistic mechanism due to the dual central and peripheral action.

Dosing Protocol

FDA-Approved Dosing (Women, HSDD)

• Dose: 1.75 mg subcutaneous injection
• Route: Autoinjector into abdomen or thigh
• Timing: At least 45 minutes before anticipated sexual activity
• Onset: Typically 60–90 minutes post-injection
• Duration: 4–6 hours
• Frequency: No more than one dose per 24 hours; no more than 8 doses per month

The monthly cap on dosing is not arbitrary — it relates to the risk of hyperpigmentation with high cumulative dosing. More on that in the side effects section.

Off-Label Dosing (Men)

In clinical practice and compounding pharmacy settings, men are typically prescribed PT-141 in the following range:

• Starting dose: 1 mg (to assess tolerability, particularly nausea)
• Effective dose range: 1–2 mg subcutaneous
• Timing: 60–90 minutes before sexual activity
• Frequency: As needed, generally not more than 2–3 times per week

Dose titration is recommended. Many men find 1.5 mg provides the desired effect with manageable side effects. Doses above 2 mg carry greater nausea risk without proportional efficacy gains.

Administration Notes

PT-141 is typically supplied as a lyophilized powder reconstituted with bacteriostatic water. Standard concentration from compounding pharmacies is 10 mg/mL. Injections are administered subcutaneously using an insulin syringe (27–31 gauge). Rotate injection sites to minimize local reactions.

Side Effects

PT-141 has a well-characterized side effect profile from clinical trials:

Nausea

Nausea is the primary limiting side effect. It typically begins 30–60 minutes post-injection, peaks around 90 minutes, and resolves within 2–3 hours. Practical strategies to reduce nausea:

• Start at the lowest effective dose (1 mg) and titrate up
• Inject on an empty stomach or light meal
• Take ondansetron (Zofran) 30 minutes before if nausea is problematic
• Avoid alcohol on the same day

Blood Pressure Effects

PT-141 causes a transient increase in blood pressure, typically 2–6 mmHg systolic, lasting 8–12 hours. For healthy individuals without cardiovascular disease, this is clinically insignificant. However, the FDA contraindicates use in patients with:

• Uncontrolled hypertension
• Known cardiovascular disease
• High cardiovascular risk

The prescribing information specifically states that bremelanotide should not be used concurrently with antihypertensive medications targeting the sympathetic nervous system, as interactions may exacerbate blood pressure effects.

Hyperpigmentation

With use exceeding 8 doses per month, focal hyperpigmentation can occur — particularly on the face, gums, and breasts. This side effect may be permanent and does not resolve upon discontinuation. This is the primary reason for the monthly dose cap, and it underscores why PT-141 should not be used casually at high frequency.

PT-141 vs. PDE5 Inhibitors: A Different Tool

PT-141 is not a replacement for sildenafil (Viagra), tadalafil (Cialis), or vardenafil. They work through entirely different pathways:

The clinical implication: PT-141 is best suited for men with psychogenic ED, low libido, or inadequate response to PDE5 inhibitors. It is not a substitute when the problem is purely vascular. However, the combination of PT-141 + a low-dose PDE5 inhibitor addresses both the desire and the mechanics simultaneously — which is why this pairing is increasingly common in men's health clinics.

Stacking PT-141 with Other Compounds

PT-141 + Sildenafil or Tadalafil

The most common clinical combination. The central desire-enhancing effect of PT-141 pairs synergistically with the peripheral vasodilatory effect of PDE5 inhibitors. Published data confirm enhanced erectile response in men who were suboptimal responders to sildenafil alone. A common approach:

• PT-141 1–1.75 mg SC, 60–90 min before activity
• Tadalafil 5–10 mg (or sildenafil 25–50 mg), taken simultaneously

PT-141 + Oxytocin

Some peptide therapy providers combine intranasal oxytocin with PT-141 for enhanced emotional intimacy alongside desire. This is largely empirical — oxytocin has pro-social and bonding effects, and its combination with PT-141's dopaminergic action is theoretically synergistic. Evidence is anecdotal at this stage.

PT-141 + BPC-157 or TB-500 (Recovery Stacks)

PT-141 is sometimes included in broader peptide protocols alongside BPC-157 or TB-500. These compounds don't directly interact with PT-141's mechanism, but men using peptides for general health optimization frequently combine them. There's no known pharmacological conflict.

Compounding and Prescriptions

The FDA-approved Vyleesi autoinjector retails for approximately $1,000 per dose — a barrier that has driven most clinical use to compounded alternatives. Compounded bremelanotide is widely available through 503A compounding pharmacies with a valid prescription and is typically priced at $10–30 per dose.

503A pharmacies fill patient-specific prescriptions. To access compounded PT-141:

1. Consult a physician (telehealth men's health or women's health clinics are the most accessible path)
2. Obtain a prescription for bremelanotide (specified dose and concentration)
3. Use a PCAB-accredited or state-licensed compounding pharmacy

Important: There is an active gray market for "research chemical" PT-141 sold without prescription. This material is not pharmaceutical grade, is not subject to USP testing, and carries real risks of contamination, dosing inaccuracy, and unknown impurities. For a compound that affects blood pressure and has documented hyperpigmentation risk, pharmaceutical-grade sourcing matters.

Who Is a Good Candidate?

PT-141 is most appropriate for:

• Premenopausal women with diagnosed HSDD — the approved indication
• Men with psychogenic ED or low libido not fully addressed by PDE5 inhibitors
• Men or women with arousal dysfunction despite normal hormone levels
• PDE5 inhibitor non-responders (as adjunctive therapy)

PT-141 is not appropriate for patients with:

• Cardiovascular disease or uncontrolled hypertension
• Current use of antihypertensives
• Pregnancy or breastfeeding
• Personal or family history of skin cancers (MC1R stimulation may promote melanogenesis)

Frequently Asked Questions

How long does PT-141 take to work?

Onset is typically 60–90 minutes after subcutaneous injection. Plan accordingly — it is not a rapid-onset drug like some PDE5 inhibitors.

Can women use PT-141?

Yes — it's actually the FDA-approved indication. Vyleesi is specifically approved for premenopausal women with HSDD. Men use it off-label.

Does PT-141 increase testosterone?

No. PT-141 does not affect the hypothalamic-pituitary-gonadal axis or testosterone levels. It works on a separate melanocortin pathway.

How often can PT-141 be used?

No more than once per 24 hours, and ideally no more than 8 times per month, to minimize hyperpigmentation risk.

Is PT-141 legal?

Bremelanotide is an FDA-approved prescription drug. Possession without a prescription is not federally illegal (it's not a controlled substance), but purchasing it without a prescription — particularly from overseas or gray-market sources — bypasses the quality controls that make pharmaceutical use safe.

Conclusion

PT-141 (bremelanotide) represents a genuinely novel approach to sexual dysfunction — one that operates at the level of brain chemistry rather than vascular mechanics. The clinical evidence supports its efficacy in women with HSDD, and growing clinical experience supports its off-label use in men, particularly those with psychogenic ED or inadequate PDE5 inhibitor response.

The side effect profile is manageable for most users, with nausea as the primary limiting factor and hyperpigmentation as the key long-term risk that mandates dose frequency limits. For appropriate candidates — particularly those who have exhausted or partially responded to first-line treatments — PT-141, ideally obtained through a licensed compounding pharmacy with a valid prescription, offers a mechanistically distinct and clinically validated option.

Disclaimer: This article is for educational purposes only. PT-141 is a prescription medication. Consult a qualified healthcare provider before use.